yahoo_financeOriginal article
MapLight Therapeutics stock crashes on Phase II schizophrenia data
Phase 2negativeNegative
AI Analysis
Summary
MapLight Therapeutics stock crashed following negative Phase II data for its schizophrenia treatment. The disappointing trial results likely represent a significant setback for the company's development program.
Clinical Trial Data
Phase
II
Primary Endpoint
Not Met
Importance:7/10
Sentiment:
-0.80
Phase IIschizophreniaclinical trialstock decline
Related Companies
Read the original article
Published by yahoo_finance on July 28, 2026 3:06 PM